Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-α receptor
Authors:
- 15 September 2008
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 112 (6) , 2484-2488
Abstract
The oral rexinoid bexarotene (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL). We recently reported the first case of adult T-cell leukemia/lymphoma (ATLL) that responded rapidly to combination therapy of bexarotene and interferon (IFN)-α2b with complete clinical response. We demonstrated that bexarotene induced apoptosis of the patient's malignant peripheral blood T-cells in vitro. However, our patient developed skin and nodal relapse 180 days after starting treatment. We now demonstrate that his peripheral blood malignant T cells became resistant to bexarotene-induced apoptosis. We investigated potential mechanisms that may cause aberrations in the retinoid X receptor (RXR) subunits, RXR-α and RXR-β, to account for these findings. Sequence analysis did not reveal acquisition of mutations in the genes encoding RXR-α and RXR-β by resistant cells. We assessed RXR-α and RXR-β expression by Western blot analysis and found that resistant cells had significantly decreased RXR-α expression compared with pretherapy bexarotene-sensitive cells. Our findings indicate that reduced expression of the RXR-α receptor subunit may represent a mechanism for resistance to bexarotene in T-cell malignancies.Keywords
This publication has 14 references indexed in Scilit:
- Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung CarcinomaStem Cells, 2006
- Lack of apoptosis of Sezary cells in the circulation following oral bexarotene therapyBritish Journal of Dermatology, 2005
- Biological Effects of Bexarotene in Cutaneous T-Cell LymphomaArchives of Dermatology, 2005
- Low-Dose Bexarotene and Low-Dose Interferon Alfa-2b for Adult T-Cell Leukemia/Lymphoma Associated With Human T-Lymphotropic Virus 1Archives of Dermatology, 2005
- Retinoid X receptors: X-ploring their (patho)physiological functionsCell Death & Differentiation, 2004
- Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanismsJournal of the American Academy of Dermatology, 2004
- The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.2002
- Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.2002
- Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.2001
- Technical tipsTrends in Genetics, 1994